Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5-6 years after completion of the primary series

• Main Authors: Juliana Park (Author), Sophia Archuleta (Author), May-Lin Helen Oh (Author), Lynette Pei-Chi Shek (Author), Jing Jin (Author), Matthew Bonaparte (Author), Carina Frago (Author), Alain Bouckenooghe (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participants aged 9-45 years at first vaccination, and who had r...